Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
Status:
Completed
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of a single dose of pexidartinib was investigated in participants with
impaired hepatic function and compared with healthy control participants with normal hepatic
function.